TB and Tobacco is a four-year project, funded by the European Union’s Horizon 2020 research and innovation programme.

The project is coordinated by the University of York (Department of Health Sciences) and involves eight other partners: ARK Foundation, Dhaka, Bangladesh; HERD International Pvt. Ltd., Kathmandu, Nepal; National TB Programme, Islamabad, Pakistan; The Initiative, Islamabad, Pakistan; Heinrich-Heine University, Düsseldorf, Germany; the University of Edinburgh, UK; the University of Leeds, UK and the General University Hospital, Prague, Czech Republic..

The aim of the project is to investigate ways in which interventions designed to encourage people to stop smoking can be integrated into tuberculosis (TB) control programmes. Our ultimate goal is to improve the health and longevity of patients suffering from TB, as well as decreasing the number of people who suffer from tobacco-related diseases

 

TB & Tobacco team at work

The research is centered on three countries that have high incidence of tobacco use and high prevalence of TB, namely Bangladesh, Nepal and Pakistan.
By studying the ‘real world’ influences on the implementation and success of stopping smoking in these contexts, the investigators hope to translate the findings of the study into real benefits for patients.

TB &Tobacco team in field

Pakistan Team
NTP( 3 members)
The Initiative( 4 members)
Field Team (At 10 project sites in Punjab and KPK)
10 Research Assistants
10 DOTs Facilitators/health Workers

TB &Tobacco team at case study site

Policy Brief:

Policy Brief: Integrating tobacco cessation within the TB programme: findings from the ‘TB & Tobacco’ study

Publications:

• Dogar O, Barua D, Boeckmann M, Elsey H, Fatima R, Gabe R, Huque R, Keding A, 
  Khan A, Kotz D, Kralikova E, Siddiqi K; TB and Tobacco project consortium. The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial. Addiction. 2018 May 30; 113 (9):1716–1726. doi: 10.1111/add.14242. [Epub ahead of print]. PubMed PMID: 29676824; PubMed Central PMCID: PMC6099220

• Dogar, Omara Fatima, Keding, Ada , Gabe, Rhian  et al. (16 more authors) (Accepted: 2020) Multicentre Randomised Double-Blind Placebo Controlled Trial of Cytisine for Smoking Cessation in Smokers with Tuberculosis. The Lancet Global Health. ISSN 2214-109X (In Press)

• Marshall, A., Barua, D., Mitchell, A., Keding, A., Huque, R., Khan, A., Zahid, R., Dogar, O. F., & Siddiqi, K. (Accepted/In press). Smoking prevalence among tuberculosis patients: a cross-sectional study in Bangladesh and Pakistan. Tobacco Induced Diseases.
• Dogar, O. et al. (2018) ‘The safety, effectiveness and cost-effectiveness of cytisine in achieving six-month continuous smoking abstinence in tuberculosis patients-protocol for a double-blind, placebo-controlled randomized trial’, Addiction . doi: 10.1111/add.14242.
• Dogar, O. F. et al. (2020) ‘Multicentre Randomised Double-Blind Placebo Controlled Trial of Cytisine for Smoking Cessation in Smokers with Tuberculosis’, The Lancet Global Health. Available at: http://eprints.whiterose.ac.uk/162580/ (Accessed: 9 November 2020).
• Marshall, A.-M. et al. (2020) ‘Smoking prevalence among tuberculosis patients: A crosssectional study in Bangladesh and Pakistan’, Tobacco induced diseases, 18, p. 70.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485439/
• Warsi, S. et al. (2019) ‘Using behaviour change theory to train health workers on tobacco cessation support for tuberculosis patients: a mixed-methods study in Bangladesh, Nepal and Pakistan’, BMC health services research, 19(1), p. 71.